The aim of this study was to investigate the prognostic impact of FGF2 and FGFR-1 expression, and their co-expressions with PDGF-B and VEGFR-3, in widely resected non-GIST STS patients. This evidence concerns the gene FGF2 and gastrointestinal stromal tumor.